269 related articles for article (PubMed ID: 25403584)
1. A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L.
Hirai F; Yamanaka T; Taguchi K; Daga H; Ono A; Tanaka K; Kogure Y; Shimizu J; Kimura T; Fukuoka J; Iwamoto Y; Sasaki H; Takeda K; Seto T; Ichinose Y; Nakagawa K; Nakanishi Y;
Ann Oncol; 2015 Feb; 26(2):363-8. PubMed ID: 25403584
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma.
Lemma GL; Lee JW; Aisner SC; Langer CJ; Tester WJ; Johnson DH; Loehrer PJ
J Clin Oncol; 2011 May; 29(15):2060-5. PubMed ID: 21502559
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of Amrubicin combined with carboplatin for thymic carcinoma and invasive thymoma: North Japan Lung Cancer group study 0803.
Inoue A; Sugawara S; Harada M; Kobayashi K; Kozuki T; Kuyama S; Maemondo M; Asahina H; Hisamoto A; Nakagawa T; Hotta K; Nukiwa T
J Thorac Oncol; 2014 Dec; 9(12):1805-9. PubMed ID: 25393793
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma.
Igawa S; Murakami H; Takahashi T; Nakamura Y; Tsuya A; Naito T; Kaira K; Ono A; Shukuya T; Tamiya A; Endo M; Yamamoto N
Lung Cancer; 2010 Feb; 67(2):194-7. PubMed ID: 19409644
[TBL] [Abstract][Full Text] [Related]
5. Study Design and Rationale for Marble Study: A Phase II Trial of Atezolizumab (MPDL3280A) Plus Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Thymic Carcinoma (JTD2101).
Asao T; Shukuya T; Mimori T; Goto Y; Tanaka H; Takayama K; Tsubata Y; Tachihara M; Suzuki T; Kaira K; Ko R; Zenke Y; Akamatsu H; Tanizaki J; Ikeda S; Sugawara S; Mizutani H; Mori K; Takahashi K
Clin Lung Cancer; 2023 Nov; 24(7):e247-e253. PubMed ID: 37316381
[TBL] [Abstract][Full Text] [Related]
6. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.
Lynch TJ; Patel T; Dreisbach L; McCleod M; Heim WJ; Hermann RC; Paschold E; Iannotti NO; Dakhil S; Gorton S; Pautret V; Weber MR; Woytowitz D
J Clin Oncol; 2010 Feb; 28(6):911-7. PubMed ID: 20100966
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of S-1 in patients with previously-treated invasive thymoma and thymic carcinoma: North Japan lung cancer study group trial 1203.
Tsukita Y; Inoue A; Sugawara S; Kuyama S; Nakagawa T; Harada D; Tanaka H; Watanabe K; Mori Y; Harada T; Hino T; Fujii M; Ichinose M
Lung Cancer; 2020 Jan; 139():89-93. PubMed ID: 31751805
[TBL] [Abstract][Full Text] [Related]
8. RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma.
Imbimbo M; Vitali M; Fabbri A; Ottaviano M; Pasello G; Petrini I; Palmieri G; Berardi R; Zucali P; Ganzinelli M; Marabese M; Broggini M; Marino M; Trama A; Rulli E; Hollander L; Pruneri G; Torri V; Garassino MC
Clin Lung Cancer; 2018 Sep; 19(5):e811-e814. PubMed ID: 30033090
[TBL] [Abstract][Full Text] [Related]
9. Combination chemotherapy with carboplatin and paclitaxel for advanced thymic cancer.
Furugen M; Sekine I; Tsuta K; Horinouchi H; Nokihara H; Yamamoto N; Kubota K; Tamura T
Jpn J Clin Oncol; 2011 Aug; 41(8):1013-6. PubMed ID: 21742653
[TBL] [Abstract][Full Text] [Related]
10. An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy With Necitumumab Versus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer.
Spigel DR; Luft A; Depenbrock H; Ramlau R; Khalil M; Kim JH; Mayo C; Chao GY; Obasaju C; Natale R
Clin Lung Cancer; 2017 Sep; 18(5):480-488. PubMed ID: 28365238
[TBL] [Abstract][Full Text] [Related]
11. Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC).
Joerger M; von Pawel J; Kraff S; Fischer JR; Eberhardt W; Gauler TC; Mueller L; Reinmuth N; Reck M; Kimmich M; Mayer F; Kopp HG; Behringer DM; Ko YD; Hilger RA; Roessler M; Kloft C; Henrich A; Moritz B; Miller MC; Salamone SJ; Jaehde U
Ann Oncol; 2016 Oct; 27(10):1895-902. PubMed ID: 27502710
[TBL] [Abstract][Full Text] [Related]
12. Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy.
Zucali PA; De Pas T; Palmieri G; Favaretto A; Chella A; Tiseo M; Caruso M; Simonelli M; Perrino M; De Vincenzo F; Toffalorio F; Damiano V; Pasello G; Garbella E; Ali M; Conforti F; Ottaviano M; Cioffi A; De Placido S; Giordano L; Bertossi M; Destro A; Di Tommaso L; Santoro A
J Clin Oncol; 2018 Feb; 36(4):342-349. PubMed ID: 29240542
[TBL] [Abstract][Full Text] [Related]
13. Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301.
Miyauchi E; Inoue A; Usui K; Sugawara S; Maemondo M; Saito H; Fujita Y; Kato T; Suzuki T; Harada T; Watanabe H; Nakagawa T; Ichinose M
Oncologist; 2017 Jun; 22(6):640-e59. PubMed ID: 28526722
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of S-1 treatment as palliative-intent chemotherapy for previously treated advanced thymic carcinoma.
Okuma Y; Goto Y; Ohyanagi F; Sunami K; Nakahara Y; Kitazono S; Kudo K; Tambo Y; Kanda S; Yanagitani N; Horiike A; Horinouchi H; Fujiwara Y; Nokihara H; Yamamoto N; Nishio M; Ohe Y; Hosomi Y
Cancer Med; 2020 Oct; 9(20):7418-7427. PubMed ID: 32813912
[TBL] [Abstract][Full Text] [Related]
15. Artemis: A Multicenter, Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of First-Line Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas.
Okuma Y; Nomura S; Sakakibara-Konishi J; Tsukita Y; Murakami S; Hosomi Y; Tambo Y; Kogure Y; Yoshioka H; Tamiya M; Ninomiya K; Iwama E
Clin Lung Cancer; 2024 Jun; 25(4):389-394. PubMed ID: 38413246
[TBL] [Abstract][Full Text] [Related]
16. Combination carboplatin and nab-paclitaxel as a first-line treatment for advanced thymic carcinoma.
Manaka H; Igawa S; Yamamoto M; Oguri A; Manabe H; Kasajima M; Kusuhara S; Hosotani S; Nakahara Y; Sato T; Fukui T; Hisashi M; Sasaki J; Naoki K
Invest New Drugs; 2023 Feb; 41(1):115-121. PubMed ID: 36633784
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer.
Lara PN; Douillard JY; Nakagawa K; von Pawel J; McKeage MJ; Albert I; Losonczy G; Reck M; Heo DS; Fan X; Fandi A; Scagliotti G
J Clin Oncol; 2011 Aug; 29(22):2965-71. PubMed ID: 21709202
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab in combination with paclitaxel and platinum for previously treated advanced thymic epithelial tumors.
Wang CL; Gao LT; Lyu CX; Zhang Q; Zeng WQ; Fang WT; Zhu L; Fu XL
Med Oncol; 2022 Jan; 39(2):25. PubMed ID: 34982283
[TBL] [Abstract][Full Text] [Related]
19. Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy in chemotherapy naïve patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase II trial.
Nakao A; Uchino J; Igata F; On R; Ikeda T; Yatsugi H; Hirano R; Sasaki T; Tanimura K; Imabayashi T; Tamiya N; Kaneko Y; Yamada T; Nagata N; Watanabe K; Kishimoto J; Takayama K; Fujita M
Invest New Drugs; 2018 Oct; 36(5):903-910. PubMed ID: 29846848
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancer.
Reck M; Krzakowski M; Chmielowska E; Sebastian M; Hadler D; Fox T; Wang Q; Greenberg J; Beckman RA; von Pawel J
Lung Cancer; 2013 Dec; 82(3):441-8. PubMed ID: 24148258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]